{"id":"daclinza-and-sunvepra","safety":{"commonSideEffects":[{"rate":"15-20","effect":"Headache"},{"rate":"10-15","effect":"Fatigue"},{"rate":"5-10","effect":"Nausea"},{"rate":"5-10","effect":"Diarrhea"},{"rate":"5-10","effect":"Insomnia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Daclatasvir (Daklinza) is an NS5A inhibitor that prevents the formation of the viral replication complex, while sofosbuvir (Sovaldi) is a nucleotide analog that inhibits the NS5B RNA-dependent RNA polymerase. Together, they provide a potent combination therapy that targets two critical steps in the hepatitis C virus lifecycle, achieving high cure rates across multiple genotypes.","oneSentence":"Daclatasvir and sofosbuvir are direct-acting antivirals that inhibit hepatitis C virus NS5A and NS5B polymerase proteins, respectively, to block viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:32:03.928Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus infection (genotypes 1-6)"},{"name":"Hepatitis C in treatment-naïve and treatment-experienced patients"},{"name":"Hepatitis C with compensated cirrhosis"}]},"trialDetails":[{"nctId":"NCT02639585","phase":"PHASE4","title":"Efficacy and Safety of Daclatasvir Plus Asunaprevir in Chronic Hepatitis C","status":"UNKNOWN","sponsor":"Pusan National University Hospital","startDate":"2015-12","conditions":"Hepatitis C, Chronic","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Daclinza and Sunvepra","genericName":"Daclinza and Sunvepra","companyName":"Pusan National University Hospital","companyId":"pusan-national-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Daclatasvir and sofosbuvir are direct-acting antivirals that inhibit hepatitis C virus NS5A and NS5B polymerase proteins, respectively, to block viral replication. Used for Chronic hepatitis C virus infection (genotypes 1-6), Hepatitis C in treatment-naïve and treatment-experienced patients, Hepatitis C with compensated cirrhosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}